Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. 

Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
112 (est)+26%
Epizyme was founded in 2007 and is headquartered in Cambridge, US

Key People/Management at Epizyme

Robert A. Copeland

Robert A. Copeland

Executive Vice President and Chief Scientific Officer

Epizyme Office Locations

Epizyme has an office in Cambridge
Cambridge, US (HQ)
400 Technology Square

Epizyme Financials and Metrics

Epizyme Financials

Epizyme's revenue was reported to be $8 m in FY, 2016
USD

Net income (Q1, 2017)

(32.5 m)

EBIT (Q1, 2017)

(33 m)

Market capitalization (20-Oct-2017)

995.3 m

Cash (31-Mar-2017)

64.4 m
Epizyme's current market capitalization is $995.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.5 m41.4 m2.6 m8 m

Revenue growth, %

(40%)(94%)213%

R&D expense

91.5 m

General and administrative expense

28.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

17.5 m22.2 m57.1 m20.6 m16.8 m17.7 m21.5 m23.9 m24.7 m

General and administrative expense

5.3 m5.7 m5.2 m6 m6.7 m5.8 m7.4 m7.5 m8.3 m

Operating expense total

22.8 m27.9 m62.3 m26.5 m23.5 m23.6 m28.9 m31.4 m33 m

EBIT

(13.3 m)(19.7 m)(61.4 m)(25.8 m)(23.1 m)(23.1 m)(28.4 m)(24.8 m)(33 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

123.6 m190.1 m208.3 m77.9 m

Accounts Receivable

33.7 m2.1 m262 k23 k

Inventories

2.4 m2.8 m4.5 m6.5 m

Current Assets

159.7 m195 m213.1 m248.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

229.9 m211.7 m244.5 m236.7 m229.9 m312.7 m89.5 m66 m64.4 m

Accounts Receivable

2.2 m2.1 m365 k723 k177 k176 k60 k6.2 m8 k

Current Assets

234.7 m217.1 m247.4 m239.4 m232.6 m318.3 m296.6 m275 m220 m

PP&E

2.6 m2.7 m5.2 m4.9 m4.5 m3.8 m3.6 m3.3 m3.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.5 m)(55 m)(132.4 m)(110.2 m)

Depreciation and Amortization

703 k742 k1.4 m1.6 m

Accounts Receivable

(32 m)31.6 m1.8 m239 k

Inventories

(1.5 m)(419 k)(1.6 m)(1.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.3 m)(40 m)(61.3 m)(25.8 m)(23.1 m)(22.9 m)(28 m)(24.3 m)(32.5 m)

Depreciation and Amortization

362 k548 k260 k389 k

Accounts Receivable

31.5 m31.6 m1.7 m723 k177 k86 k60 k6.2 m8 k

Accounts Payable

(142 k)1.1 m(3.2 m)3 m3 m(2.4 m)3.7 m3.4 m7.3 m
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

Epizyme Market Value History

Traffic Overview of Epizyme

Epizyme Online and Social Media Presence

Epizyme Company Life and Culture

You may also be interested in